Literature DB >> 9030105

Use of NASBA RNA amplification for detection of Mycobacterium leprae in skin biopsies from untreated and treated leprosy patients.

G M van der Vliet1, S N Cho, K Kampirapap, J van Leeuwen, R A Schukkink, B van Gemen, P K Das, W R Faber, G P Walsh, P R Klatser.   

Abstract

This study was performed to assess the value of NASBA RNA amplification of a 16S rRNA target for the detection of presumably viable Mycobacterium leprae in sections of skin biopsies from leprosy patients. The NASBA positivity rate was 90.4% (84/93) for untreated multibacillary (MB) patients [bacterial index (BI) > or = 2] and 16.7% (8/48) for the untreated paucibacillary (PB) patients (BI < 2). NASBA positivity showed a good concordance with the presence of solidly stained M. leprae [morphological index (MI)] in skin biopsies from leprosy patients, but no relationship could be demonstrated between the strength of the NASBA signals and the BI. Furthermore, the usefulness of the detection of 16S rRNA by NASBA to monitor the efficacy of leprosy treatment was investigated using an additional 154 biopsy specimens analyzed from 80 MB patients during the course of treatment. The NASBA positivity rate declined during treatment. A significant decrease was observed after only 1-3 months. These results favor the view that detection of RNA by NASBA may reflect the viability of M. leprae.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9030105

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  8 in total

Review 1.  Characteristics and applications of nucleic acid sequence-based amplification (NASBA).

Authors:  Birgit Deiman; Pierre van Aarle; Peter Sillekens
Journal:  Mol Biotechnol       Date:  2002-02       Impact factor: 2.695

2.  Improved detection of rhinoviruses by nucleic acid sequence-based amplification after nucleotide sequence determination of the 5' noncoding regions of additional rhinovirus strains.

Authors:  K Loens; M Ieven; D Ursi; C De Laat; P Sillekens; P Oudshoorn; H Goossens
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

3.  Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples.

Authors:  Wendy F van der Meide; Gerard J Schoone; William R Faber; Jim E Zeegelaar; Henry J C de Vries; Yusuf Ozbel; Rudy F M Lai A Fat; Leíla I A R C Coelho; Masoom Kassi; Henk D F H Schallig
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Detection of live and antibiotic-killed bacteria by quantitative real-time PCR of specific fragments of rRNA.

Authors:  Steve Aellen; Yok-Ai Que; Bertrand Guignard; Marisa Haenni; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

5.  Immunohistological analysis of in situ expression of mycobacterial antigens in skin lesions of leprosy patients across the histopathological spectrum. Association of Mycobacterial lipoarabinomannan (LAM) and Mycobacterium leprae phenolic glycolipid-I (PGL-I) with leprosy reactions.

Authors:  C Verhagen; W Faber; P Klatser; A Buffing; B Naafs; P Das
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

6.  Detection of Mycoplasma pneumoniae in spiked clinical samples by nucleic acid sequence-based amplification.

Authors:  K Loens; D Ursi; M Ieven; P van Aarle; P Sillekens; P Oudshoorn; H Goossens
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

7.  Simplified molecular detection of Leishmania parasites in various clinical samples from patients with leishmaniasis.

Authors:  Claire M Mugasa; Thierry Laurent; Gerard J Schoone; Frank L Basiye; Alfarazdeg A Saad; Sayda El Safi; Piet A Kager; Henk Dfh Schallig
Journal:  Parasit Vectors       Date:  2010-03-02       Impact factor: 3.876

Review 8.  Current and Future Perspectives on Isothermal Nucleic Acid Amplification Technologies for Diagnosing Infections.

Authors:  Godwin Attah Obande; Kirnpal Kaur Banga Singh
Journal:  Infect Drug Resist       Date:  2020-02-12       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.